Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
Pharmaceuticals	199.65M
Total	199.65M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
People's Republic of China (PRC)	198.98M
Uzbekistan	674.00K
Total	199.65M

Source: S&P Global Market Intelligence.